98 related articles for article (PubMed ID: 36948059)
1. MRI phenotypes associated with breast cancer predisposing genetic variants, a multisite review.
Maimone S; Harper LK; Mantia SK; Advani PP; Hochwald AP; Li Z; Hines SL; Patel B
Eur J Radiol; 2023 May; 162():110788. PubMed ID: 36948059
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
3. Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers.
Ghunaim H; Laenen A; De Keyzer F; Soens J; Keupers M; Postema S; Neven P; Van Ongeval C
Eur J Radiol; 2022 Jan; 146():110074. PubMed ID: 34902667
[TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
5. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract][Full Text] [Related]
6. Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
Ha SM; Chae EY; Cha JH; Kim HH; Shin HJ; Choi WJ
AJR Am J Roentgenol; 2017 Oct; 209(4):920-928. PubMed ID: 28796549
[TBL] [Abstract][Full Text] [Related]
7. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.
; Mavaddat N; Dorling L; Carvalho S; Allen J; González-Neira A; Keeman R; Bolla MK; Dennis J; Wang Q; Ahearn TU; Andrulis IL; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Briceno I; Brüning T; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Christiansen H; Czene K; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; Geisler J; Giles GG; Guénel P; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Hartikainen JM; Hartman M; Hoppe R; Howell A; Jakubowska A; Jung A; Khusnutdinova EK; Kristensen VN; Li J; Lim SH; Lindblom A; Loizidou MA; Lophatananon A; Lubinski J; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Morra A; Muir K; Obi N; Osorio A; Park-Simon TW; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Thorne H; Tomlinson I; Torres D; Truong T; Yip CH; Spurdle AB; Vreeswijk MPG; Dunning AM; García-Closas M; Pharoah PDP; Kvist A; Muranen TA; Nevanlinna H; Teo SH; Devilee P; Schmidt MK; Easton DF
JAMA Oncol; 2022 Mar; 8(3):e216744. PubMed ID: 35084436
[TBL] [Abstract][Full Text] [Related]
8. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.
Paixão D; Torrezan GT; Santiago KM; Formiga MN; Ahuno ST; Dias-Neto E; Tojal da Silva I; Foulkes WD; Polak P; Carraro DM
Front Oncol; 2022; 12():976959. PubMed ID: 36119527
[TBL] [Abstract][Full Text] [Related]
9. Correlation between imaging features and molecular subtypes of breast cancer in young women (≤30 years old).
Huang J; Lin Q; Cui C; Fei J; Su X; Li L; Ma J; Zhang M
Jpn J Radiol; 2020 Nov; 38(11):1062-1074. PubMed ID: 32562180
[TBL] [Abstract][Full Text] [Related]
10. MR Imaging Findings in Molecular Subtypes of Breast Cancer According to BIRADS System.
Navarro Vilar L; Alandete Germán SP; Medina García R; Blanc García E; Camarasa Lillo N; Vilar Samper J
Breast J; 2017 Jul; 23(4):421-428. PubMed ID: 28067435
[TBL] [Abstract][Full Text] [Related]
11. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
13. Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants.
Hudson L; Gower N; Lenarcic S; Trufan SJ; White RL
Ann Surg Oncol; 2020 Jul; 27(7):2248-2254. PubMed ID: 31974710
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations.
Bergstrom C; Pence C; Berg J; Partain N; Sadeghi N; Mauer C; Pirzadeh-Miller S; Gao A; Li H; Unni N; Syed S
Ann Surg Oncol; 2021 Jun; 28(6):3383-3393. PubMed ID: 32996020
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
16. Can enhancement types on preoperative MRI reflect prognostic factors and surgical outcomes in invasive breast cancer?
Koh J; Park AY; Ko KH; Jung HK
Eur Radiol; 2019 Dec; 29(12):7000-7008. PubMed ID: 31187220
[TBL] [Abstract][Full Text] [Related]
17. Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.
Bychkovsky BL; Agaoglu NB; Horton C; Zhou J; Yussuf A; Hemyari P; Richardson ME; Young C; LaDuca H; McGuinness DL; Scheib R; Garber JE; Rana HQ
JAMA Oncol; 2022 Nov; 8(11):1598-1606. PubMed ID: 36136322
[TBL] [Abstract][Full Text] [Related]
18. Frequency of Pathogenic Germline Variants in
Petridis C; Arora I; Shah V; Moss CL; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1162-1168. PubMed ID: 31263054
[TBL] [Abstract][Full Text] [Related]
19. MR imaging phenotypes and features associated with pathogenic mutation to predict recurrence or metastasis in breast cancer.
Shao Z; Yu J; Cheng Y; Ma W; Liu P; Lu H
BMC Cancer; 2023 Jan; 23(1):97. PubMed ID: 36707770
[TBL] [Abstract][Full Text] [Related]
20. Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review.
Pavlovica K; Irmejs A; Noukas M; Palover M; Kals M; Tonisson N; Metspalu A; Gronwald J; Lubinski J; Murmane D; Kalnina A; Loza P; Maksimenko J; Trofimovics G; Subatniece S; Daneberga Z; Miklasevics E; Gardovskis J
Eur J Med Genet; 2022 May; 65(5):104477. PubMed ID: 35314380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
